A BH3 Mimetic for Killing Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer cells evade apoptosis, a natural cell death process.
• Elevated BCL-2 protein levels in cancer cells inhibit pro-apoptotic proteins.
• This inhibition makes cancer cells resistant to cell death signals.

Purpose of the Study:

• To describe Venetoclax as a novel therapeutic agent.
• To explain the mechanism of action of Venetoclax in cancer treatment.
• To highlight Venetoclax's role in targeting protein-protein interactions.

Main Methods:

• Venetoclax is a BH3 mimetic drug.
• It targets the BCL-2 protein, a key regulator of apoptosis.
• It disrupts the interaction between BCL-2 and pro-apoptotic proteins.

Main Results:

• Venetoclax effectively releases the inhibition of pro-apoptotic proteins by BCL-2.
• This action re-sensitizes cancer cells to apoptosis.
• It represents a new therapeutic strategy for cancers with high BCL-2 expression.

Conclusions:

• Venetoclax is the first approved drug to target a protein-protein interaction.
• It offers a novel approach to cancer therapy, particularly for chronic lymphocytic leukemia.
• Its mechanism involves reactivating the intrinsic apoptosis pathway.